Sodium-Glucose Transporter 2 Inhibitors: all 1,276 studies that test it

Page 13 of 13. Open to participants first (266), then studies with results posted, then the rest; newest registration first within each.

• Mass Balance Study of ASP1941CompletedNCT01302132Phase 1
• Renal Impairment Study With ASP1941CompletedNCT01302028Phase 1
• A Pharmacodynamics, Pharmacokinetics, and Safety Study of Hydrochlorothiazide and Canagliflozin in Healthy VolunteersCompletedNCT01294631Phase 1
• A Study to Evaluate the Interaction of LX4211 and Metformin in Healthy SubjectsCompletedNCT01292993Phase 1
• Multiple Dose Escalating Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1941CompletedNCT01288898Phase 1
• First in Men Study of Single Oral Doses of ASP1941 in Healthy SubjectsCompletedNCT01288885Phase 1
• A Pharmacokinetic and Pharmacodynamic Study of Once-Daily and Twice-Daily Dosing With Canagliflozin in Healthy Adult VolunteersCompletedNCT01286103Phase 1
• A Single and Multiple Dose Study of Canagliflozin in Healthy VolunteersCompletedNCT01281579Phase 1
• A Pharmacokinetic and Pharmacodynamic Study of Metformin and Canagliflozin in Healthy Adult VolunteersCompletedNCT01273571Phase 1
• A Study of Two Methods for Determining the Renal Threshold for Glucose in Patients With Type 2 Diabetes MellitusCompletedNCT01273558Phase 1
• Evaluation of Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise AloneSuspendedNCT01257412Phase 3
• Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a SulfonylureaStatus unknownNCT01257334Phase 3
• A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic PatientsCompletedNCT01242228Phase 3
• A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic PatientsCompletedNCT01242202Phase 3
• A Study of the Effect of ASP1941 on Cardiac Repolarization in Healthy SubjectsCompletedNCT01232413Phase 1
• A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Pioglitazone in Type 2 Diabetic PatientsCompletedNCT01225081Phase 3
• Evaluation of Pharmacokinetics, Safety, And Tolerability Of Ertugliflozin (PF-04971729, MK-8835) In Japanese And Western Healthy Participants (MK-8835-041)CompletedNCT01223339Phase 1
• A Drug Interaction Study of Warfarin and Canagliflozin in Healthy Adult VolunteersCompletedNCT01195324Phase 1
• Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes MellitusCompletedNCT01188863Phase 1
• A Study to Assess the Effect of Hepatic Function on the Pharmacokinetics and Safety of ASP1941CompletedNCT01187186Phase 1
• A Study of Canagliflozin in Study Participants With Various Degrees of Impaired Hepatic (Liver) FunctionCompletedNCT01186588Phase 1
• A First-in-Human Study of JNJ-28431754 in Healthy Male VolunteersCompletedNCT01177150Phase 1
• Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)CompletedNCT01165268Phase 1
• A Pharmacokinetic and Bioavailability Study of 28431754 (Canagliflozin) in Healthy Male VolunteersCompletedNCT01157000Phase 1
• Study to Assess the Effect of Food on Combination Dapagliflozin/Metformin Tablet in Healthy VolunteersCompletedNCT01156246Phase 1
• Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy SubjectsCompletedNCT01135446Phase 1
• A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Type 2 Diabetic PatientsCompletedNCT01135433Phase 3
• A Pharmacokinetic and Pharmacodynamic Study to Determine Blood Levels of JNJ-28431754 (Canagliflozin) in Patients With Type 2 Diabetes MellitusCompletedNCT01128985Phase 1
• A Radiolabeled Mass Balance Study of [14C]-Ertugliflozin (PF04971729, MK-8835) In Healthy Male Participants (MK-8835-038)CompletedNCT01127308Phase 1
• A Study to Assess Safety and Tolerability of ASP1941 After Single and Repeated Administration in Healthy SubjectsCompletedNCT01121198Phase 1
• A Study to Evaluate the Effect of ASP1941 in Combination With Metformin in Adult Patients With Type 2 Diabetes MellitusCompletedNCT01117584Phase 2
• Study To Estimate The Relative Bioavailability of Ertugliflozin (PF-04971729, MK-8835) in Healthy Adult Participants (MK-8835-039)CompletedNCT01114568Phase 1
• A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Sitagliptin When Given Together to Healthy SubjectsCompletedNCT01104532Phase 1
• A Study to Assess Drug-Drug Interaction Between ASP1941 and MiglitolCompletedNCT01099839Phase 1
• A Study to Assess the Pharmacokinetics, Pharmacodynamics of ASP1941 in Diabetes Mellitus Patients With Renal ImpairmentCompletedNCT01097681Phase 1
• A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Pioglitazone Hydrochloride When Given Together to Healthy SubjectsCompletedNCT01088919Phase 1
• A Study to to Assess the Effect of Dapagliflozin When Administered Once a Day Versus Twice a Day on Blood GlucoseCompletedNCT01072578Phase 1
• A Study to Evaluate the Effect of ASP1941 in Adult Patients With Type 2 Diabetes MellitusCompletedNCT01071850Phase 2
• Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy SubjectsTerminatedNCT01068756Phase 1
• A Study to Assess the Efficacy and Safety of ASP1941 in Japanese Type 2 Diabetes PatientsCompletedNCT01057628Phase 3
• A Study Comparing the Amount of Metformin and After Taking a Combination Tablet vs. Separate TabletsCompletedNCT01055691Phase 1
• Drug-drug Interaction Study of Dapagliflozin With Voglibose in Japanese Type 2 Diabetes Mellitus PatientsCompletedNCT01055652Phase 1
• A Study to Assess the Long-term Safety and Efficacy of ASP1941 in Japanese Diabetic PatientsCompletedNCT01054092Phase 3
• A Study of ASP1941 in Japanese Patients With Type 2 Diabetes MellitusCompletedNCT01023945Phase 1
• A Multiple Dose Study Of Ertugliflozin (PF-04971729, MK-8835) In Otherwise Healthy Overweight And Obese Volunteers (MK-8835-037)CompletedNCT01018823Phase 1
• Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II DiabeticsStatus unknownNCT01001962Phase 4
• A Single Escalating Dose Study Of Ertugliflozin (PF-04971729, MK-8835) Under Fed and Fasted Conditons In Healthy Volunteers (MK-8835-036)CompletedNCT00989079Phase 1
• A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes MellitusCompletedNCT00963768Phase 1
• Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy SubjectsCompletedNCT00930865Phase 1
• Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy SubjectsCompletedNCT00908271Phase 1
• Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy SubjectsCompletedNCT00904176Phase 1
• Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy SubjectsCompletedNCT00842556Phase 1
• Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy SubjectsCompletedNCT00839683Phase 1
• A Study to Assess the Safety and Tolerability of ASP1941 in Adults With Type 2 Diabetes Mellitus.CompletedNCT00790660Phase 2
• Renal Mechanism of Action/Splay vs. TmGTerminatedNCT00726505Phase 1
• Effects of Single Oral Dose Dapagliflozin QT StudyCompletedNCT00688493Phase 1
• A Study To Compare Effects Of GSK189075 In Combination With Either Furosemide Or HydrochlorothiazideCompletedNCT00671424Phase 1
• A Study to Assess the Safety of Repeated Doses of GSK189075 and WELLBUTRIN SR in Healthy Male SubjectsCompletedNCT00625859Phase 1
• A Study of ASP1941 in Participants With Type 2 Diabetes MellitusCompletedNCT00621868Phase 2
• Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy SubjectsCompletedNCT00562250Phase 1
• A Study to Compare the Safety and Drug Levels in Blood When Using Various Forms of GSK189075 Given to Healthy SubjectsCompletedNCT00559884Phase 1
• Renal Impairment in Type 2 Diabetic SubjectsCompletedNCT00554450Phase 1
• Drug Interaction With MetforminCompletedNCT00546741Phase 1
• Phase I Multiple-Ascending Dose (Japan)CompletedNCT00538174Phase 1
• A Study to Compare the Effect on Heart Rhythm of 3 Days of GSK189075, Placebo, or Moxifloxacin in Healthy AdultsCompletedNCT00532610Phase 1
• A Study To Assess The Safety And Tolerability Of GSK189075 When Given With A Total Daily Dose Of >/ 2000mg of MetforminCompletedNCT00519480Phase 1
• A Study of the Effects of GSK189075 on PK Profiles of an Oral Contraceptive Pill When Given to Healthy Female VolunteersCompletedNCT00504816Phase 1
• A Study to Evaluate and Study Drug Levels in Blood Plasma When Giving High Doses of GSK189075 to Healthy VolunteersCompletedNCT00501930Phase 1
• A Comparison Of Study Drug Blood Levels After One Dose Of GSK189075 In Subjects With Normal And Reduced Kidney FunctionCompletedNCT00501462Phase 1
• A Study of the Effects of Ketoconazole Taken Orally Has on the PK Profiles of a Dose of GSK189075 in Healthy VolunteersCompletedNCT00501397Phase 1
• Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active DrugsCompletedNCT00494767Phase 1
• Drug Interactions From Simultaneous Administration Of Metformin And GSK189075 To Subjects With Type 2 DiabetesCompletedNCT00376038Phase 1
• Dose-Ranging Study Evaluating AVE2268 in Patients With Type 2 Diabetes Not Adequately Controlled by a Metformin TreatmentCompletedNCT00361738Phase 2
• GSK189075, GW869682 Or Placebo In Type 2 Diabetic PatientsCompletedNCT00291356Phase 2
• A Trial of BMS-512148 in Patients With Type 2 Diabetes MellitusCompletedNCT00263276Phase 2
• A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic SubjectsCompletedNCT00162305Phase 2

← Sodium-Glucose Transporter 2 Inhibitors overview